10 results
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
Over-anticoagulation ... lead to severe bleeding ... #treatment #medications ... #decisionaid #cardiology ... #hematology #warfarin
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
at high risk of bleeding ... interactions and bleeding ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... thrombosis; PE = pulmonary ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... DOACs thereby leading ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Triggers: ATRA treatment ... Release from blast cells ... Imaging: CXR- pulmonary ... diagnosis #management #hematology ... #oncology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
ecchymoses, mucosal bleeding ... number of CD34+ cells ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #hematology #diagnosis
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
unusual bruising or bleeding ... are caused by bleeding ... factor (GCSF) treatments ... Syndromes #diagnosis #hematology ... #oncology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
with presence of pulmonary ... causing hypovolemia needing ... algorithm #management #cardiology ... #treatment #table ... icu #clinical #pharmacology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Disease: • 10%-15% Pulmonary ... , INC risk PE, Pulmonary ... Nephrogenic DI Hematologic ... Adenocarcinoma Treatment ... lubricants • Pharmacologic
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
cardiomyopathy • Pulmonary ... Period • Breast-feeding ... suggest prophylactic anticoagulation ... diagnosis #management #cardiology ... #treatment